GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Marksans Pharma Ltd (NSE:MARKSANS) » Definitions » Price-to-Free-Cash-Flow

Marksans Pharma (NSE:MARKSANS) Price-to-Free-Cash-Flow : N/A (As of May. 12, 2024)


View and export this data going back to 2002. Start your Free Trial

What is Marksans Pharma Price-to-Free-Cash-Flow?

As of today (2024-05-12), Marksans Pharma's share price is ₹159.25. Marksans Pharma's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was ₹0.00. Hence, Marksans Pharma's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Marksans Pharma's Price-to-Free-Cash-Flow or its related term are showing as below:

NSE:MARKSANS' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 0   Med: 13.75   Max: 157.04
Current: 36

During the past 13 years, Marksans Pharma's highest Price-to-Free-Cash-Flow Ratio was 157.04. The lowest was 0.00. And the median was 13.75.

NSE:MARKSANS's Price-to-Free-Cash-Flow is ranked worse than
66.6% of 500 companies
in the Drug Manufacturers industry
Industry Median: 22.74 vs NSE:MARKSANS: 36.00

Marksans Pharma's Free Cash Flow per Share for the three months ended in Dec. 2023 was ₹0.00. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was ₹0.00.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 1.50% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 65.30% per year.

During the past 13 years, Marksans Pharma's highest 3-Year average Free Cash Flow per Share Growth Rate was 127.80% per year. The lowest was -54.40% per year. And the median was 17.80% per year.


Marksans Pharma Price-to-Free-Cash-Flow Historical Data

The historical data trend for Marksans Pharma's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marksans Pharma Price-to-Free-Cash-Flow Chart

Marksans Pharma Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 71.70 3.28 15.47 35.19 15.91

Marksans Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 15.91 - - -

Competitive Comparison of Marksans Pharma's Price-to-Free-Cash-Flow

For the Drug Manufacturers - General subindustry, Marksans Pharma's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Marksans Pharma's Price-to-Free-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Marksans Pharma's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Marksans Pharma's Price-to-Free-Cash-Flow falls into.



Marksans Pharma Price-to-Free-Cash-Flow Calculation

Marksans Pharma's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=159.25/0
=N/A

Marksans Pharma's Share Price of today is ₹159.25.
Marksans Pharma's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Marksans Pharma  (NSE:MARKSANS) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Marksans Pharma Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Marksans Pharma's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Marksans Pharma (NSE:MARKSANS) Business Description

Traded in Other Exchanges
Address
Veera Desai Extension Road, 11th Floor, Grandeur, Opposite Gundecha Symphony, Oshiwara, Andheri (West), Mumbai, MH, IND, 400053
Marksans Pharma Ltd is a pharmaceutical company. The company is engaged in the research, manufacturing, and marketing of pharmaceutical formulations. It manufactures analgesics, gastroenterology, anti-diabetic, cardiovascular, pain management, gynecology, gastrointestinal and oncologic drugs as well as antibiotics and antiallergic medications. It has a market presence with the majority of the revenue generated from the United States and North America, followed by Europe and the UK, Australia and New Zealand, India, and the Rest of the World.

Marksans Pharma (NSE:MARKSANS) Headlines

No Headlines